Raises 2025 revenue guidance to $915 to$925 million, representing growth of 24% to 25% PALO ALTO, Calif. July 30, 2025 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights For the three-month period ended June 30, 2025, as compared to the same period of 2024: Recent Operating Highlights "Q2 was another exceptional quarter for Guardant and we were able to increase our 2025 re ...